C L Deal

Summary

Affiliation: Cleveland Clinic Foundation
Country: USA

Publications

  1. doi request reprint Recent recommendations on steroid-induced osteoporosis: more targeted, but more complicated
    Chad L Deal
    Department of Rheumatic and Immunologic Disease, Cleveland Clinic, Cleveland, OH 44195, USA
    Cleve Clin J Med 80:117-25. 2013
  2. doi request reprint Bone loss in rheumatoid arthritis: systemic, periarticular, and focal
    Chad Deal
    Center for Osteoporosis and Metabolic Bone Disease, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine at Case Western, University School of Medicine, OH, 44122, USA
    Curr Rheumatol Rep 14:231-7. 2012
  3. doi request reprint Emerging therapies for osteoporosis
    Chad Deal
    Orthopedic and Rheumatology Institute, Department of Rheumatology, Center for Osteoporosis and Metabolic Bone Disease, Cleveland, OH, USA
    Rheum Dis Clin North Am 37:337-50, v. 2011
  4. ncbi request reprint Raloxifene: a selective estrogen-receptor modulator for postmenopausal osteoporosis - a clinical update on efficacy and safety
    Chad L Deal
    Center for Osteoporosis and Metabolic Bone Disease, Department of Rheumatic and Immunology Diseases A50, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Womens Health (Lond Engl) 2:199-210. 2006
  5. doi request reprint Future therapeutic targets in osteoporosis
    Chad Deal
    Center for Osteoporosis and Metabolic Bone Disease, Department of Rheumatology, Orthopedic and Rheumatology Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Curr Opin Rheumatol 21:380-5. 2009
  6. doi request reprint Potential new drug targets for osteoporosis
    Chad Deal
    Orthopedic and Rheumatology Institute, Cleveland Clinic, Cleveland, OH 44195, USA corrected
    Nat Clin Pract Rheumatol 5:20-7. 2009
  7. ncbi request reprint Absolute fracture risk
    Chad L Deal
    Center for Osteoporosis and Metabolic Bone Disease, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Rheumatol Rep 9:66-70. 2007
  8. ncbi request reprint The United States rheumatology workforce: supply and demand, 2005-2025
    Chad L Deal
    Department of Rheumatology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Arthritis Rheum 56:722-9. 2007
  9. ncbi request reprint The use of intermittent human parathyroid hormone as a treatment for osteoporosis
    Chad Deal
    Center for Osteoporosis and Metabolic Bone Disease, Department of Rheumatology, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Rheumatol Rep 6:49-58. 2004
  10. ncbi request reprint Using bone densitometry to monitor therapy in treating osteoporosis: pros and cons
    C L Deal
    Center for Osteoporosis and Metabolic Disease, The Cleveland Clinic Foundation, Department of Rheumatic and Immunologic Diseases, 9500 Euclid Avenue, Desk A 50, Cleveland, OH 44195, USA
    Curr Rheumatol Rep 3:233-9. 2001

Collaborators

Detail Information

Publications12

  1. doi request reprint Recent recommendations on steroid-induced osteoporosis: more targeted, but more complicated
    Chad L Deal
    Department of Rheumatic and Immunologic Disease, Cleveland Clinic, Cleveland, OH 44195, USA
    Cleve Clin J Med 80:117-25. 2013
    ..They outline a more targeted approach but have the possible disadvantage of being more complicated and therefore harder to use...
  2. doi request reprint Bone loss in rheumatoid arthritis: systemic, periarticular, and focal
    Chad Deal
    Center for Osteoporosis and Metabolic Bone Disease, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine at Case Western, University School of Medicine, OH, 44122, USA
    Curr Rheumatol Rep 14:231-7. 2012
    ..The term osteoimmunology has evolved to highlight the association between cells and cytokines of the immune system and their relationship to bone metabolism in rheumatoid arthritis and other forms of chronic inflammatory arthritis...
  3. doi request reprint Emerging therapies for osteoporosis
    Chad Deal
    Orthopedic and Rheumatology Institute, Department of Rheumatology, Center for Osteoporosis and Metabolic Bone Disease, Cleveland, OH, USA
    Rheum Dis Clin North Am 37:337-50, v. 2011
    ..Novel anabolic agents in development include antibodies that target molecules involved in Wnt signaling...
  4. ncbi request reprint Raloxifene: a selective estrogen-receptor modulator for postmenopausal osteoporosis - a clinical update on efficacy and safety
    Chad L Deal
    Center for Osteoporosis and Metabolic Bone Disease, Department of Rheumatic and Immunology Diseases A50, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Womens Health (Lond Engl) 2:199-210. 2006
    ..Raloxifene use is associated with a higher incidence of hot flashes and leg cramps, and an increased risk of venous thromboembolic events...
  5. doi request reprint Future therapeutic targets in osteoporosis
    Chad Deal
    Center for Osteoporosis and Metabolic Bone Disease, Department of Rheumatology, Orthopedic and Rheumatology Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Curr Opin Rheumatol 21:380-5. 2009
    ....
  6. doi request reprint Potential new drug targets for osteoporosis
    Chad Deal
    Orthopedic and Rheumatology Institute, Cleveland Clinic, Cleveland, OH 44195, USA corrected
    Nat Clin Pract Rheumatol 5:20-7. 2009
    ....
  7. ncbi request reprint Absolute fracture risk
    Chad L Deal
    Center for Osteoporosis and Metabolic Bone Disease, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Rheumatol Rep 9:66-70. 2007
    ..This model will allow identification of patients who would benefit most from treatment...
  8. ncbi request reprint The United States rheumatology workforce: supply and demand, 2005-2025
    Chad L Deal
    Department of Rheumatology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Arthritis Rheum 56:722-9. 2007
    ..To develop and apply a model that allows prediction of current and future supply and demand for rheumatology services in the US...
  9. ncbi request reprint The use of intermittent human parathyroid hormone as a treatment for osteoporosis
    Chad Deal
    Center for Osteoporosis and Metabolic Bone Disease, Department of Rheumatology, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Rheumatol Rep 6:49-58. 2004
    ..Patients with hypercalcemia and hyperparathyroidism also should not receive the drug...
  10. ncbi request reprint Using bone densitometry to monitor therapy in treating osteoporosis: pros and cons
    C L Deal
    Center for Osteoporosis and Metabolic Disease, The Cleveland Clinic Foundation, Department of Rheumatic and Immunologic Diseases, 9500 Euclid Avenue, Desk A 50, Cleveland, OH 44195, USA
    Curr Rheumatol Rep 3:233-9. 2001
    ..This article reviews the use of bone densitometry as a tool for monitoring treatment in patients with low bone mass...
  11. ncbi request reprint Risedronate prevents hip fractures, but who should get therapy?
    Chad L Deal
    Center for Osteoporosis and Metabolic Bone Disease, Department of Rheumatic and Immunologic Diseases, The Cleveland Clinic Foundation, OH 44195, USA
    Cleve Clin J Med 69:964, 968-70, 973-6. 2002
    ..Patients should be selected for bisphosphonate therapy on the basis of low bone density. A history of vertebral fractures increases the risk for hip fractures...
  12. ncbi request reprint Successes and failures in improving osteoporosis care after fragility fracture: results of a multiple-site clinical improvement project
    J Timothy Harrington
    University of Wisconsin School of Medicine and Public Health, Madison, WI 53715, USA
    Arthritis Rheum 55:724-8. 2006
    ..To improve osteoporosis diagnosis and treatment of fragility fracture patient populations because osteoporosis care is provided infrequently to those patients, leaving them vulnerable to further fractures and increasing debility...